Searched for
HATCH WAXMAN ACT
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringementMayne Pharma sued India's Sun Pharma for allegedly infringing patents on IMVEXXY, a drug for menopause-related vaginal pain. The lawsuit wa...- Indian pharma – time for a cyclical upturn in US generics?Due to absent competition, such drugs become huge cash cows for innovator companies. Titans in this space include companies like Gilead Sci...
- Mylan-Biocon’s insulin biosimilar faces FDA hurdleFirms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.
- Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
- Teva may move court against Dr Reddy's for patent infringementThe Israeli drug maker already is involved in various legal battles with other drug firms over the patent litigations of Copaxone.
- Amarin Pharma files patent infringement case against Dr Reddy's Laboratories on lipid lowering drug, VascepaAmarin Pharma has filed a patent case against Dr Reddy's Labs alleging that the latter is attempting to come out with generic versions of V...
- Sanofi files cases against Glenmark on patent infringementSanofi had submitted its application to seek US Food and Drug Administration's (USFDA's) approval for its generic version of the drug on Ja...
- Ranbaxy shares fall over 5% as trouble brews in US marketThe stock plunged over 5% on reports that the US-based Ohm Laboratories-the company's facility in US, is under the surveillance of FDA.
- Glenmark confirms patent challenge for its generic versions of VIMPAT in the US CourtGlenmark Generics Ltd confirms that it has filed ANDAs for Lacosamide tablets and oral solution with the US drug authorities with a Paragra...
- Sun Pharma takes Novartis to US Court, seeks permission to market Glivec in USUntil and unless Sun obtains a court decision of non-infringement and/or invalidity on the ’051 patent, it faces the risk of patent infring...
- Ranbaxy drug gets US nodRanbaxy Laboratories got the exclusive rights to market a generic version of Japanese firm Eisai's blockbuster Alzheimer's drug in the US f...
- Ranbaxy settles drug dispute with Takeda, US launch in 2012Ranbaxy Laboratories Ltd on Monday said it has entered into an agreement with the Japanese drug maker Takeda Pharmaceuticals for ending the...
- Sun's Caraco settles litigation with Forest Lab in USThe Rs 4,300-crore Sun Pharmaceuticals Ltd's US-subsidiary, Caraco Pharmaceuticals Laboratories Ltd, has gone for settlement of the legal p...
- '14 years of data exclusivity is crazy'William Haddad, chairman and CEO of Biogenerics spoke on the immense potential Indian generic manufacturers have in the global market. Exce...
- Indian pharma players to benefit from generic drugs in USIncreased use of generic drugs helped the US healthcare system save billions of dollars over last decade. 6 mysteries about swine flu | Swi...
- Lupin settles case with WyethLupin has struck an out-of-court settlement with Wyeth relating to the foreign company’s antidepressant ‘Effexor XR’ capsules.
- Glenmark confirms patent challenge of fluticasone lotionGlenmark Generics Ltd's US subsidiary confirmed Nycomed US filed a patent infringement lawsuit on Dec 12, 2008, in the US District Court, E...
- Abbott files patent suit against Zydus Cadila in US courtUS-based Abbott Laboratories seeks to stop the Indian company, Zydus Cadila, from selling generic version of its drug, Depakote, in the US.
- Pharma patent disputes out-of-courtUnder such settlements, cos agree to delay entrance in market for certain benefits, such as licences to other patents.
- Ranbaxy wins 180-day exclusivity for simvastatinThe US Court of Appeals has upheld the 180-day exclusivity of Ranbaxy’s cholesterol-lowering drug simvastatin, reports Our Bureau. It has a...
Load More
